Precision Drug Delivery to the Liver: A Nanoparticle Approach

The global burden of Chronic Liver Diseases (CLDs) is escalating, with increasing prevalence and mortality. Various conditions ranging from fibrosis, cirrhosis, and hepatocellular carcinoma are associated with conditions such as toxin accumulation, viral infections, and metabolic derangements. In this already difficult context, the emergence of metabolic dysfunction-associated steatotic liver disease and steatohepatitis complicated the picture even further. While there has been much advancement in medical research, there is currently no standard cure; hence, the best treatment options are limited, providing a rising need for new therapeutic approaches. Nanoparticle drug delivery systems represent a promising avenue, providing targeted delivery and enhanced therapeutic effectiveness. Nanosystems can protect therapeutic agents from degradation, evade rapid clearance mechanisms, and target drugs directly to a specific hepatic cell type. However, the complex architecture of the liver presents challenges for these therapies, including the need to precisely target individual cells and retain the stability of nanoparticles within the hepatic microenvironment. This review presents recent advances in nanoparticle and targeted ligands-based technologies. These technologies help to navigate barriers associated with similar therapies. As these challenges are addressed, nanotechnological advancements could potentially lead to a major revolution in the treatment of CLDs, paving the way for improved management strategies and providing new hope for affected individuals worldwide.